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Collagenous Gastritis in Children: Incidence, Disease
Course, and Associations With Autoimmunity and
Inflammatory Markers
Timo Käppi, MD1,2, Alkwin Wanders, MD, PhD3,4, Mats Wolving, MD5, Christine Lingblom, PhD6, Birgitta Davidsson Bården, MD7,
Rikard Arkel, MD8, Josefine Hätting, MD9, Johan Anderzén, MD10, Christine Wennerås, MD, PhD6,11 and Robert Saalman, MD, PhD1,2
INTRODUCTION: Collagenous gastritis (CG), a rare disorder of unknown etiology, has been postulated to have immune-
mediatedmechanisms. We investigated (i) the incidence and prevalence of CG in a pediatric population;
(ii) the clinical, endoscopic, and histologic characteristics of childhood-onset CG; and (iii) the evidence
for autoimmunity and/or inflammatory activity in these patients.
METHODS: Clinical, endoscopic, and histologic data were reviewed longitudinally in a population-based Swedish
cohort of 15 patients with childhood-onset CG diagnosed in the period 2008–2019. A set of 11
autoantibodies, 4 blood inflammatory biomarkers, and the human leukocyte antigen DQ2/DQ8 genotype
was analyzed cross-sectionally.
RESULTS: The incidence rate of childhood-onset CGwas0.25/100,000person-years,with an incidence rate ratio of
girls toboysof4.2 (95%confidence interval, 1.2–15). TheprevalenceofCGwas2.1/100,000 inchildren
aged younger than 18 years. The endoscopic and histologic findings remained pathologic in all the
examined patients during a median follow-up of 4.4 years. Many patients had heredity for autoimmune
disorders (47%) and/or tested positive for autoantibodies (40%) or human leukocyte antigen DQ2/DQ8
(53%). No associated autoimmune comorbidities were observed. The serum levels of calprotectin and
amyloid A were increased in 10/15 (67%) and 5/15 (33%) of the patients, respectively, whereas plasma
C-reactive protein levels were normal in all, but 1 patient.
DISCUSSION: The results indicate that childhood-onset CG is rare and has a chronic disease course. Although signs of
autoimmune predisposition are frequent, early development of autoimmune comorbidities seems
seldom. Serum calprotectin and amyloid A represent novel candidate biomarkers of inflammatory
activity in CG (see Visual Abstract, Supplementary Digital Content 4, http://links.lww.com/CTG/A349).
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A335, http://links.lww.com/CTG/A336, http://links.lww.com/CTG/A337
Clinical and Translational Gastroenterology 2020;11:e00219. https://doi.org/10.14309/ctg.0000000000000219
INTRODUCTION
Collagenous gastritis (CG) is a rare gastrointestinal disorder with
fewer than 300 cases reported in the English-language literature
(1–24). Of these cases, about one-third have been childhood-onset
CG (15–45). The condition is characterized histologically by an
increased subepithelial layer of collagen (conventionally defined as
being.10mmin thickness) in the gastricmucosa, togetherwith an
inflammatory cell infiltrate in the lamina propria (46,47). In most
pediatric cases of CG, the collagenous mucosal inflammation is
restricted to the stomach (22–24,41), whereas in adult-onset dis-
ease, concurrent involvement of the small bowel and/or colon is
more common (1,23,24,46,48). Pediatric cases of CG generally
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present with severe iron deficiency anemia and/or recurrent ab-
dominal pain (22–24,41), whereas diarrhea andmalabsorption are
the predominant symptoms in adults, presumably linked to the
frequently observed concurrent intestinal involvement (32,46,49).
Associated immune-mediated comorbidities, such as celiac disease
and type 1 diabetes, have been reported in both pediatric
(22–24,26,31) and adult (3–5,23,24,45,47,50) patients. CG is be-
lieved to be a chronic disease, and there is currently no effective
treatment (46).
The current literature on childhood-onset CG consists mainly
of case reports (15–20,27–37,42,43,51), apart from 6 small case
series (21,22,38–41) and 3 histopathologic studies with limited
clinical information and follow-up data (23,24,45). Consequently,
the knowledge regarding the evolution of the clinical, endoscopic,
and histologic features of the disease over time is sparse. Further-
more, although immune-mediated/autoimmune disease mecha-
nisms have been hypothesized (47), convincing supporting
evidence is lacking. In collagenous colitis, the human leukocyte
antigen (HLA) DQ2.5 haplotype, encoded by the HLA DQ2/DQ8
genes, seems to be associated with increased disease susceptibility
(52). However, no studies of the prevalence of the HLADQ2/DQ8
haplotype in CG have been published. Moreover, the methodolo-
gies used in the previous studies of CG have not allowed estima-
tions of the disease incidence or prevalence, although a possible
female predominance has been noted (1,41).
The aims of this population-based cohort study, which com-
bines longitudinal and cross-sectional approaches and involves
15 patients with childhood-onset CG, were to investigate: (i) the
incidence and prevalence of CG in a pediatric population in
western Sweden; (ii) the clinical, endoscopic, and histologic
characteristics of childhood-onset CG through the course of the
disease; and (iii) the frequencies of autoimmune comorbidities
and heredity, as well as the prevalences of autoantibody de-
velopment, increased blood inflammatory biomarkers, and the
HLADQ2/DQ8 haplotypes in patients with childhood-onset CG.
METHODS
Study design
The study was designed as a population-based cohort study that
comprised 15 persons of White ethnicity with childhood-onset
CG (12 female and 3male patients) and age range of 8.7–23 years
(median age, 15 years) recruited from western Sweden. All cases
of CG diagnosed before the age of 18 years in the counties of
Halland, Jönköping, Värmland, and Västra Götaland in western
Sweden during the period of January 2008 through June 2019
were identified. These 4 counties comprise 26% of the Swedish
population and in 2019 had a pediatric population (aged ,18
years) of approximately 568,000 (53). The Department of Pedi-
atric Gastroenterology, Hepatology, and Nutrition at Queen Sil-
via Children’s Hospital, Gothenburg, Sweden, which serves as a
tertiary referral center for these counties, was involved in the
diagnosis of all the cases. Furthermore, an established practice in
Sweden is that all pediatric endoscopies are performed under
general anesthesia in county hospitals or higher-level medical
institutions within the public healthcare system. This enables the
identification of all eligible cases within the geographic area
covered by the study. The recruitment of subjects was carried out
at a clinical follow-up visit during the period of May 2019 to
November 2019, at which time point all the blood samples were
drawn. All eligible patients accepted to participate in the study.
Diagnostic criteria
The diagnosis of CG was based on histologic demonstration of
increased (.10mm) subepithelial collagen deposition in at least 1
biopsy taken from gastric mucosa during endoscopy, in addition
to other histologic, endoscopic, and clinical findings supporting
the diagnosis (32,47). The day when the first endoscopic exami-
nation thatmet the diagnostic criteria was performedwas defined
as the date of diagnosis.
Epidemiological analyses
The incidence rate of childhood-onset CG for the period spanning
January 2008 to June 2019 was calculated according to the recom-
mended principles for dynamic populations (54). To define the
population at risk, the data on the annual numbers of children aged
younger than 18 years registered in the counties of Halland,
Jönköping, Värmland, and Västra Götaland during the period
2008–2019 were retrieved from the Swedish Government agency
Statistics Sweden. The prevalence of CG in the population aged
younger than18years in the4countieswas calculatedasof June2019.
Clinical, endoscopic, and histologic data
The complete medical records and endoscopic reports for all the
patients were reviewed. Demographic data, existing comorbid-
ities, clinical symptoms related to CG, and outcomes from tested
treatment modalities were retrieved during the follow-up con-
sultations. Furthermore, heredity for autoimmune and other
diseases among first-degree relatives was systemically evaluated.
Regarding the histopathologic evaluation, all cases had ini-
tially been re-evaluated by a senior gastrointestinal pathologist
(M.W.) at the Department of Pathology, Sahlgrenska University
Hospital, Gothenburg, Sweden, to confirm the diagnosis. For the
purpose of this study, the gastric mucosal biopsies from all gas-
trointestinal endoscopies performed on study subjects during the
follow-up were reviewed independently by a different senior
gastrointestinal pathologist (A.W.). In this evaluation, the specific
histologic parameters recently proposed for CG, such as the
location of collagen deposits, the grade of active and chronic
inflammation, and the presence of eosinophil- or lymphocyte-
predominant type of inflammation in the gastric mucosa, were
applied (23). In addition, themaximumnumber of intraepithelial
eosinophilic granulocytes per high-power field (size, 0.24 mm2)
was determined. Moreover, the maximal thicknesses of the sub-
epithelial collagen deposits in gastric mucosal biopsies were
measured using an ocular micrometer in the microscope and
collagen-specific stains (i.e., Masson trichrome, Van Gieson, or
Sirius Red). Furthermore, mucosal biopsies acquired from other
sites in the gastrointestinal tract were also reviewed, and any
diagnostic abnormalities were recorded.
Laboratory parameters
All the blood laboratory parameters were analyzed on inclusion of
the patient in the study, and they included 11 autoantibody spec-
ificities and 4 inflammatorymarkers. The following autoantibodies
weremeasured in the serum samples: antinuclear antibody (ANA),
antismooth muscle antibody, antimitochondrial antibody, anti-
neutrophil cytoplasmic antibody, tissue transglutaminase IgA,
antithyrotropin receptor antibodies, antithyroid peroxidase anti-
bodies, antithyroglobulin antibodies, antiglutamic acid decarbox-
ylase antibodies, antiintrinsic factor antibodies, and antiparietal cell
antibodies. The blood inflammatory markers analyzed were
plasma C-reactive protein (CRP), serum calprotectin, serum
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amyloid A (SAA), and serum orosomucoid. The values of all the
inflammatory parameters were continuous, with the exception of
SAA, which had a detection limit of 11 mg/L with the analysis
method used.
In addition, genotyping of HLA DQ2/DQ8 was performed.
Moreover, the serum levels of albumin, blood total leukocyte
counts, and blood absolute neutrophil counts, as well as the total
serum levels of immunoglobulins A, M, and G (including IgG
subclasses), were measured. The laboratory methods used and the
cutoff levels and reference intervals applied in the study are listed in
Tables S1a and S1b (see Supplementary Digital Content 1, http://
links.lww.com/CTG/A335). All blood samples were drawn after a
12-hour period of fasting and analyzed in accredited laboratories at
Sahlgrenska University Hospital, Gothenburg, Sweden, or at affil-
iated county hospitals. The blood analysis laboratory data were
complete for all the study participants, with the exception of a
blood absolute neutrophil count that was missing for a single
patient.
Ethics
Written informed consent was obtained from all study partici-
pants and/or their parents. The study was approved by the Re-
gional Ethical ReviewBoard ofGothenburg,Gothenburg, Sweden
(Dnr. 298-12).
Statistical methods
Owing to the limited sample size and non-normal distribution of
the variables, the data are presented as medians with ranges. To
calculate the confidence interval for the incidence rate ratio, a
2-sample z-test was applied. The Spearman test was used for
determination of correlations between laboratory parameters. A
2-tailed P-value ,0.05 was considered statistically significant.
The z-test was performed using Microsoft Excel for Mac 2011
version 14.7.7 software (Microsoft, Redmond,WA). For all other
statistical analyses, IBM SPSS Statistics version 22 software (IBM,
New York, NY) was used.
RESULTS
Patient characteristics
The median age at the diagnosis of CG was 9.9 years (range,
4.4–17 years), whereas the median age at the initial presentation
was 9.8 years (range, 4.3–16 years). The median duration of
disease, measured from the initial presentation, was 6.2 years
(range, 0.4–11 years) on inclusion in the study. The collagenous
inflammation was restricted to the stomach in all, but 2 patients
(13/15, 87%), and associated collagenous duodenitis and collag-
enous colitis were seen in 1 patient each. No patient had an
established current or previous comorbidity involving other
gastrointestinal, autoimmune, or inflammatory diseases. Allergic
disease was seen in 2 (13%) patients, both of whom suffered from
allergic rhinoconjunctivitis. Apart from 1 patient with concom-
itant collagenous colitis who was receiving budesonide therapy
and 3 other patients who were being treated with proton pump
inhibitors, the remaining 11 patients were not receiving any anti-
inflammatory or immunosuppressive therapy.
Incidence rate and prevalence
The annual number of persons aged younger than 18 years at risk
for CG in the study’s geographic area was in the range of
505,414–565,425 (corresponding to approximately 20%of the total
population) during the study period and consisted predominantly
of persons ofCaucasian ancestry. The total number of person-years
of follow-up (PYFU) in this population-based cohort was
6,020,927, which translates to an incidence rate of childhood-onset
CG of 0.25 cases per 100,000 PYFU during the study period. Cat-
egorized by sex, the incidence rate for CG was 0.41 cases per
100,000 PYFU for girls and 0.097 cases per 100,000 PYFU for boys,
yielding an incidence rate ratio (girls to boys) of 4.2 (95% confi-
dence interval, 1.2–15). In June 2019, the prevalence of CG in
children aged younger than 18 years was 2.1/100,000 in the
counties of western Sweden.
Clinical picture and disease course
All but 1 patient had iron deficiency anemia on initial pre-
sentation, and in most of the cases, this was severe (Table 1). The
chief complaint that prompted the patient to seek medical at-
tention was related to the anemia (e.g., fatigue and pallor) in 5/15
patients (33%) or to gastrointestinal symptoms in 3/15 patients
(20%). In the remaining 7 cases (47%), the iron deficiency anemia
that initiated the diagnostic workup was an incidental finding,
discovered when the patients were seeking medical attention for
reasons unrelated to anemia or gastrointestinal symptoms, such
as a respiratory infection.
In a targeted anamnesis, recurrent abdominal painwas reported
by 6/15 patients (45%) on presentation, although in most of the
cases, the pain was not severe and did not affect the activities of
daily living. However, in the sole patient with associated collage-
nous colitis, the presenting symptoms were dominated by watery
diarrhea. None of the patients showed hematemesis, melena, or
hematochezia. Nonetheless, testing for fecal hemoglobin was car-
ried out in 12/15 patients (80%) as part of the initial diagnostic
workup. The testing did not indicate occult gastrointestinal
bleeding in any of these patients. In 10of the 12girls in the study, all
of whom had iron deficiency anemia at presentation, the diagnosis
of CG was made before menarche. The remaining 2 girls reported
nomenorrhagia. At presentation, all the patients were on a regular
diet, and no one was taking any medication.
All 14 patients who had iron deficiency anemia at presentation
responded to iron supplementation with normalization of blood
hemoglobin levels and iron parameters. After initial treatment,
iron deficiencywith orwithout associated anemia recurredwithin
a median time of 1 year (range, 1–2 years) in 13 of the patients,
most of whom continued to require repeated iron substitution
subsequently during the follow-up. Orally delivered iron sup-
plementation (ferrous asparto glycinate plus polysaccharide iron
complex or iron sulphate) was the primary choice of therapy, and
intravenous administration of iron (ferric carboxymaltose) was
used primarily when oral intake of iron created bothersome
gastrointestinal side effects, such as abdominal pain. Apart from
the recurrence of iron deficiency, most of the patients remained
asymptomatic during the median follow-up of 6.2 years (range,
1.0–11 years). Only 1 patient experienced recurrent abdominal
pain that affected daily activities, whereas another patient who
had concurrent collagen colitis experienced occasional bouts of
watery diarrhea despite maintenance therapy with budesonide.
Treatment outcomes
Efforts were made to treat CG with proton pump inhibitors (n5
5) and dietary modifications (n5 7), such as cow’s milk-free diet
(n5 4), gluten-free diet (n5 2), and diet free of cow’s milk, soy,
egg, and wheat (n 5 1). However, none of the patients showed
endoscopic or histologic improvements during the treatment
American College of Gastroenterology Clinical and Translational Gastroenterology
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Table 1. Chief complaints, blood hemoglobin levels, erythrocyte indices, and serum iron parameters at presentation of 15 patients with childhood-onset collagenous gastritis
Patient code Sex Age (yr) Chief complaint(s)
Hb (g/L)
[RI: 115–160]
MCV (fL)
[RI: 75–102]
MCHC (g/L)
[RI: 310–370]
Iron (mmol/L)
[RI: 9–34]
Ferritin (mg/L)
[RI: 20–200]
TIBC (mmol/L)
[RI: 48–83]
sTfR (mg/mL)
[RI: 1.9–5.0]
TS (%)
[RI: 6–48]
A M 4.6 Fatigue, pallor 28 52 255 ,1.0 1.9 nd 54.0 2
B F 10.1 Fatigue, pallor 49 54 285 1.7 2 100 57.5 2
C F 13.1 Fatigue, pallor, palpitation 79 68 306 2.1 3 110 16.3 3
D F 14.4 Fatigue, pallor, palpitation, headache 39 62 244 1.5 2 83 35.4 3
E F 12.7 Fatigue, vertigo 40 64 233 0.6 ,2 99 35.8 nd
F F 9.8 Recurrent abdominal pain, non-bloody
diarrhea
94 59 280 nd 3 nd nd nd
G M 8.3 Recurrent abdominal pain,
gastroesophageal reflux
137 83 350 nd nd nd nd nd
H F 4.3 Watery, non-bloody diarrhea 105 80 309 3 6 nd 7.6 nd
I F 12.5 Incidental finding of anemia 78 58 261 1 ,2 73 nd nd
J M 7.8 Incidental finding of anemia 73 60 245 nd 2 nd nd nd
K F 5.9 Incidental finding of anemia 59 61 267 2 4 nd nd nd
L F 16.0 Incidental finding of anemia 55 55 273 1.2 2 95 60.1 2
M F 13.0 Incidental finding of anemia 50 55 262 1.4 2 83 58.3 2
N F 8.8 Incidental finding of anemia 47 68 274 1.8 2 110 30.7 2
O F 8.6 Incidental finding of anemia 88 62 319 5 ,2 74 2.84a nd
Hb, Hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; nd, no data; RI, reference interval; sTfR, soluble transferrin receptor; TIBC, total iron-binding capacity; TS, transferrin
saturation.
aAnalyzed at affiliated hospital laboratory with nephelometry-based method with reference interval of 0.80–1.76 mg/mL.
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Table 2. Endoscopic and histologic findings at the time of diagnosis of collagenous gastritis for the patients in the study cohort
Patient
code Sex
Age
(yr)
Current
therapy Macroscopic findings
Histologic findings in gastric mucosal biopsies
Other associated
pathology
Max. collagen
thickness (mm)
Location of
collagen
Collagen
distributiona
Eos/
HPF
IEL/
HPF
A M 5.8 None Edematous and nodular
mucosa in gastric body and
fundus; traces of coagulated
blood
40 Corpusb Patchy 40 ,25 None
B F 10.9 None Nodularity in gastric antrum 20 Equal antrum and corpus Focal ,15 ,25 None
C F 13.9 None Nodularity in proximal
part of gastric antrum
60 Equal antrum and corpus Patchy 70 ,25 None
D F 15.4 None Nodularity in gastric antrum, body
and fundus; mild erythema
in gastric antrum
40 Equal antrum and corpus Patchy 30 ,25 Subtotal villous atrophy in
proximal duodenum;
intraepithelial lymphocytosis
in proximal and distal
duodenumd
E F 13.1 None Hypertrophic and nodular mucosa with
slight erythema in gastric body
100 Corpus predominant Patchy 90 ,25 None
F F 9.9 None Nodularity in gastric body and antrum 60 Antral predominant Patchy 40 ,25 None
G M 8.5 PPI Mucosal irritation in gastric body and
antrum; nodular changes in duodenal bulb
40 Corpus predominant Diffuse 100 ,25 None
H F 4.4 None Unremarkable 40 Antrumc Focal 30 ,25 Total villous atrophy
without intraepithelial
lymphocytosis in duodenume;
collagenous colitis
I F 12.6 None Nodularity in gastric body 55 Corpus predominant Patchy 40 ,25 None
J M 8.0 None Nodularity with a few erosions
in gastric body and fundus
80 Equal antrum and corpus Patchy 150 ,25 Total villous atrophy,
intraepithelial lymphocytosis
and collagen deposits
in proximal duodenumd
K F 6.4 None Nodularity in gastric
body and fundus
30 Corpus predominant Patchy 50 ,25 None
L F 17.0 None Erythema and raised mucosal
stripes in gastric body and
antrum; cobblestone
appearance in antrum
80 Equal antrum and corpus Diffuse 60 ,25 None
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period (see Table S2, Supplementary Digital Content 2, http://
links.lww.com/CTG/A336). Apart from the patient with con-
current collagenous colitis whowas onmaintenance therapy with
budesonide, no steroids or immunomodulators were adminis-
tered to any of the remaining 14 patients.
Endoscopic and histologic features
The endoscopic and histologic findings in the gastric mucosa in
the patient cohort at the time of diagnosis are listed in Table 2.
The endoscopic appearance of the gastric mucosa was judged to
be abnormal in all, but 1 case. However, this patient had aberrant
macroscopic findings in the stomach in follow-up endoscopies.
The most commonly observed endoscopic features were mucosal
nodularity, hypertrophic gastric folds, and erythema. Only 1
patient demonstrated endoscopic signs of mucosal bleeding from
the stomach. Biopsy-based tests showed no signs of concurrent
Helicobacter pylori gastritis in any patient.
Histologically, the maximal thickness of the subepithelial colla-
gen deposits was in the range of 15–100mmat diagnosis.Moreover,
most (13/15, 87%) of the patients exhibited an eosinophil-rich ($30
eosinophils/high-power field) inflammation of the gastric mucosa,
with up to 150 eosinophils/high-power field. By contrast, intra-
epithelial lymphocytosis (.25 surface intraepithelial lymphocytes/
100 epithelial cells) was seen in only 1 patient.
Duodenalmucosal biopsies had been acquired from all patients
on diagnosis ofCG, and 3patients showed an associated subtotal or
total villous atrophy with or without intraepithelial lymphocytosis
(Table 2). One of these patients had collagen deposits in the duo-
denal bulb consistent with collagenous gastroduodenitis and tested
negative for celiac disease in serologic tests. In the other 2 cases, no
collagen depositswere detected in the duodenal biopsies (including
follow-up endoscopies), and the serologic tests did not support a
finding of celiac disease (see Table S2, Supplementary Digital
Content 2, http://links.lww.com/CTG/A336).However, at the time
of this study, aweak increase in the levels of tissue transglutaminase
IgA antibodies had developed in one of these 2 patients, indicating
that celiac disease was under development, thereby necessitating
additional diagnostic work-up.
Follow-up gastroscopies with gastric and duodenal mucosal
biopsies had been performed for 11/15 patients (73%), with the
median time from the diagnosis to the latest gastroscopy being 4.4
years (range, 1.4–7.4 years). None of these patients had evidence
of endoscopic or histologic normalization of the gastric mucosal
pathology, including persistence of .10 mm-thick subepithelial
collagen deposits in gastric mucosal biopsies (see Table S2, Sup-
plementary Digital Content 2, http://links.lww.com/CTG/A336).
However, there was no worsening of the mucosal inflammation
over time, and no patient developed intestinal metaplasia or ad-
vanced mucosal atrophy in the gastric corpus. Furthermore, 11/
15 patients (73%) had been evaluated with at least 1 colonoscopy
withmultiplemucosal biopsies during the follow-upperiod.With
the exception of 1 patient with associated collagenous colitis, no
additional pathologies were noted in the colonic or ileal biopsies
of the remaining patients.
Autoimmune predisposition
In total, 9/15 patients (60%) had predisposition to autoimmune
disease, defined as the presence of autoimmunity-related hered-
itary factors and/or autoantibodies in the circulation (Table 3).
Approximately half (7/15, 47%) of the study subjects had he-
reditary factors for autoimmune diseases among their first-degreeT
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relatives. Moreover, 6/15 patients (40%) tested positive for au-
toantibodies. The most common autoantibody specificity detec-
ted was ANA, which was detected in a fifth (3/15, 20%) of the
cohort. One patient tested positive for antithyroid peroxidase
antibodies but had normal levels of thyroid hormones. None of
the patients tested positive for antimitochondrial antibody,
antithyroglobulin antibodies, antithyrotropin receptor anti-
bodies, antiglutamic acid decarboxylase antibodies, anti-intrinsic
factor antibodies, or antiparietal cell antibodies.More than half of
the patients (8/15, 53%) carried the HLA DQ2 or DQ8 haplo-
types. The most common haplotype was DQ2.5, which was
detected in 5/15 (33%) patients (Table 3).
Inflammatory parameters and immunoglobulins
The plasma level of CRP was discretely increased (i.e., 9 mg/mL;
reference, ,5 mg/mL) in only 1 patient. By contrast, the serum
levels of calprotectin and amyloid Awere increased in 10/15 (67%)
and 5/15 (33%) patients, respectively (Figure 1a, b). For patients
with increased values, the median level of serum calprotectin was
4,550 ng/mL (range, 3,600–11,000 ng/mL; reference, ,2,300 ng/
mL) and that of amyloid A was 22 mg/L (range, 12–55 mg/L;
reference, ,11 mg/L), respectively. In 4 of the 5 patients with
elevated SAA, serum calprotectin was concurrently increased
(Figure 1c); oneof these patients also had an increased level ofCRP.
Moreover, serum calprotectin showed a strong positive correlation
with the absolute neutrophil counts in the blood (Figure 1d), al-
though the blood total leukocyte and absolute neutrophil counts
were not above the reference range in any patient. The serum level
of albumin was slightly decreased (i.e., 32 g/L) in 1 patient, and no
patient showed increased serum levels of orosomucoid. A retro-
spective chart review revealed that erythrocyte sedimentation rate
(ESR) had been analyzed in 14/15 (93%) and CRP in 13/15 (87%)
patients during the disease course, in many cases repeatedly, and
normal values were detected in all the patients.
No patient had total serum levels of immunoglobulins con-
sistent with hypogammaglobulinemia or selective IgA deficiency,
although slightly decreased levels of IgG and IgA were seen in 3
patients (see Table S3, Supplementary Digital Content 3, http://
links.lww.com/CTG/A337). None of the patients in the cohort
had high levels of IgG4 in sera indicative of IgG4-related disease.
DISCUSSION
In this population-based study, we have investigated the clinical,
endoscopic, and histologic characteristics of childhood-onset CG
in a cohort of 15 patients during amedian follow-up period of 6.2
years from the initial presentation. The results of this study
support the view that CG in children follows a chronic disease
course and has a skewed sex distribution, with female pre-
dominance (41). Furthermore, although more than half of the
patients had hereditary factors for autoimmune diseases and/or
had developed autoantibodies, the development of autoimmune
comorbidities early in the disease course of CG was not seen. A
novel finding was that despite normal levels of plasma CRP,
the level of serum calprotectin was increased in two-thirds of the
patients and the level of SAA was increased in one-third of the
patients, indicative of systemic inflammation.
To the best of our knowledge, this is the largest cohort of CG
with longitudinal follow-up reported to date, and this is the first
Table 3. Family history of autoimmune diseases, presence of autoantibodies in serum, and HLA DQ2/D8 haplotypes in the study cohort
Patient
codea Sex
Age
(yr)
Presence of autoimmune diseases
among first-degree relatives Detected autoantibodies HLA DQ2/DQ8 haplotype
H F 15.7 Mother with celiac disease; father
with ulcerative colitis
SMA Negative
I F 13.8 Mother with hypothyreosis;
father with psoriasis
SMA DQ2.5 heterozygous
J M 8.7 Mother with hypothyreosis and latent
autoimmune diabetes in adults
ANA; anti-thyroid peroxidase
antibodies
DQ2.5 heterozygous
C F 21.1 Mother with hypothyreosis ANA DQ8 heterozygous
D F 22.7 Father with type 1 diabetes Tissue transglutaminase IgA DQ2.2 and DQ8 heterozygous
K F 12.9 Mother with celiac disease None DQ2.5 and DQ2.2 heterozygous
G M 14.8 Sister with type 1 diabetes None Negative
L F 17.2 None ANA DQ2.5 heterozygous
F F 17.4 None Atypical pANCA Negative
M F 17.3 None None DQ2.2 heterozygous
N F 11.0 None None DQ2.5 heterozygous
B F 19.3 None None Negative
O F 14.8 None None Negative
A M 9.7 None None Negative
E F 13.2 None None Negative
ANA, antinuclear antibody; pANCA, perinuclear anti-neutrophil cytoplasmic antibody; SMA, antismooth muscle antibody.
aThe codes denote the same patients as in Tables 1 and 2.
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study of such a cohort with a population-basedmethodology that
allows calculations of incidence and prevalence values. The in-
cidence rate of childhood-onset CG is 0.25/100,000 person-years
of follow-up, and the prevalence is 2.1/100,000 children aged
younger than 18 years in western Sweden, which substantiates the
idea that this is a rare disease. Furthermore, the incidence rate of
childhood-onset CG was approximately 4-fold higher in female
patients than in male patients, supporting the notion that there is
female predominance in the childhood-onset type of CG. The
skewed sex distribution has previously been suggested by aggre-
gated data frompublished reports of CG for both the pediatric age
group (41) and the whole (i.e., pediatric and adult combined)
population (1). For the associated condition of collagenous colitis,
female predominance is well documented in population-based
studies in adults, reporting female-to-male ratios of up to 9:1
(55–58).
Approximately half of the patients in our cohort exhibited he-
redity for autoimmune diseases among their first-degree relatives,
and 40%had developed autoantibodies. Thesefindings support the
view of an autoimmune/immune-mediated mechanism un-
derlying the disease process, as previously indicated mainly by the
frequent association with autoimmune comorbidities, such as ce-
liac disease, in adults with CG (1,32). The frequency of heredity for
autoimmune diseases observed in the present study is high, con-
sidering the estimated prevalence of autoimmune diseases in the
Scandinavian general population of,10% (59–61). Similarly, the
prevalences of the 2 most frequently observed autoantibody spec-
ificities in our study, ANA (20%) and antismoothmuscle antibody
(13%), can be compared with reported frequencies of,5% for the
same autoantibodies in healthy children (62,63). Interestingly, the
rate of autoantibody development is comparablewith that reported
for collagenous colitis in adult studies, e.g., ANA positivity in
10%–26% of the patients (64,65).
Although the frequencies of heredity for autoimmune diseases
and autoantibody development in our cohort are relatively high,
none of the patients developed any autoimmune disease during the
follow-up period, which extended up to 11 years from the initial
presentation. To our knowledge, in the English-language, peer-
reviewed literature to date, 10 cases with development of concomi-
tant autoimmunedisease (22–24,26,31) amonga total of 79pediatric
cases of CG have been reported (15–24,26–37,39–41,43–45).
Therefore, despite the low rate of autoimmune comorbidities ob-
served in the short term in our study, childhood-onset CGmay still
be associated with an increased long-term risk of developing these
diseases.
Half of the patients in our cohort were HLA DQ2/DQ8-
positive,which is similar to theprevalence ofDQ2/DQ8haplotypes
in the general Scandinavian population (66,67). However, the
DQ2.5 haplotype was detected in 33% of the patients, which can be
compared with the reported frequency for this haplotype of
20%–25% in healthy controls in Scandinavian studies (52,67,68).
There are no previous studies on the prevalence of the HLA DQ2/
DQ8 in patients with CG. Notably, however, the frequency of the
DQ2.5 haplotype in adult patients with collagenous colitis has been
reported as 32%–45% (52,69,70), with 1 report providing data to
support an association between the DQ2.5 haplotype and an in-
creased risk of collagenous colitis (52).
A novel finding of the present study is that the serum levels of
calprotectin and amyloid A are increased in two-thirds and one-
third of the patients, respectively. This suggests that serum
Figure 1. Levels of (a) serum calprotectin and (b) serum amyloid A in the cohort of 15 patients with childhood-onset collagenous gastritis. The cutoffs
(indicated by dashed lines) applied were$2,300 ng/mL for serum calprotectin and$11 mg/L for serum amyloid A, respectively. The analysis method for
serumamyloid A had a detection limit of 11mg/L and the values below that level are given as zero. Relationship between serum levels of calprotectin and (c)
serum amyloid A and (d) blood absolute neutrophil counts (n5 14). The correlation coefficient (r) with 95%confidence interval (CI) was determined using
the Spearman test. The open triangle indicates the single patient in the cohort with concurrent collagen colitis.
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calprotectin in particular, but also SAA, is more sensitive than
CRP for estimating the severity of inflammatory activity in pa-
tients with CG. To our knowledge, serum calprotectin and SAA
have not previously been investigated in relation to CG. Although
a few previous reports have provided data on inflammatory
markers in childhood-onset CG, those studies have limited
themselves to examining CRP and ESR (16,31–34,39,41). In
keeping with our results, those previous studies have demon-
strated normal levels of CRP and/or ESR in children with iso-
lated CG.
Serum calprotectin and SAA have been proposed as comple-
mentary blood biomarkers to CRP andESR formonitoring disease
activity in other inflammatory conditions, such as rheumatoid
arthritis (71–75) and inflammatory bowel disease (71,76–79).
Calprotectin is produced by activated neutrophils and monocytes
both locally at the site of inflammation and in the circulation (80),
but the acute-phase protein SAA is synthesized by the hepatocytes
in the liver (81).Although the increased serum levels of calprotectin
noted in the present study may reflect in part local mucosal in-
flammation, the increased levels of SAA are indicative of systemic
inflammation. Moreover, the positive association observed be-
tween serum calprotectin levels and blood absolute neutrophil
counts has previously been reported for patients with in-
flammatory bowel disease (79) and cardiovascular disease (82).
In our cohort, the collagenous inflammationwas confined to the
stomach in all but 2 patients who had concurrent collagenous
duodenitis and colitis, respectively. This rarity of concurrent col-
lagenous inflammation in other parts of the digestive tract is con-
sistent with the compiled results of previous pediatric reports.
Overall, 79 pediatric patients with CGhave, to our knowledge, been
reported in the peer-reviewed, English-language literature to date
(15–24,26–37,39–41,43–45). Of these, only 7 patients have con-
current collagenous colitis (22–24,26,40) and 4 patients have con-
current collagenous inflammation in the small bowel (17,23,24,39).
In 3 additional reported cases, the collagenous inflammation affects
all 3 locations in the gastrointestinal tract (24,30,35). This contrasts
with adult patients, in whom CG is predominantly seen in combi-
nation with collagenous inflammation engaging the small bowel
and/or colon (1,23,24).
The pathologic endoscopic and histologic features of CG per-
sisted in all the study participants for whom follow-up endoscopies
were performed, indicating a chronic disease course without
spontaneous improvement. The endoscopic picturewas dominated
by mucosal nodularity, hypertrophic gastric folds, and erythema,
which have been reported also by others as the most common
findings in cases of childhood-onset CG (22–24,41). Histologically,
a variation in the thickness of the subepithelial collagen bands in the
gastric mucosa was noticed between different patients and longi-
tudinally in the samepatient. Thismight be attributable to sampling
bias and the patchy distribution of subepithelial collagen bands in
the gastric mucosa. The same explanation might be forwarded for
the spontaneous “resolution” of collagen deposits previously
reported for a few patients with CG (23).
Regarding the inflammatory cell infiltrate in the gastric mu-
cosa, the histologic profiles of most of the patients were charac-
terized by an eosinophil-rich inflammation, whereas increased
intraepithelial lymphocytosis was seen in only 1 patient at di-
agnosis. This is in line with previous histopathologic studies, in
which an eosinophil-rich inflammatory infiltrate was apparent in
50%–62% of the children with CG, but a lymphocytic gastritis-
like pattern was seen in,10% of the cases (23,24). The opposite
has been noted in adults with CG, in whom the eosinophil-rich
inflammation seems to be less prevalent, whereas the lymphocytic
gastritis-like pattern may be more common, as compared with
children with CG (23,24).
Iron deficiency anemia was the dominant feature in the clinical
picture of childhood-onset CG in this study. It was observed in
approximately 90% of the patients at the initial presentation. Fur-
thermore, iron deficiency with or without associated anemia
showed a high rate of recurrence. Our results are in accordancewith
the few small case series of childhood-onset CG published to date,
which have reported a variable prevalence of anemia (up to 92%) at
presentation (22–24). The recurrence of iron deficiency has also
been reported to be common (21,22). It is plausible that the high
prevalence of iron deficiency observed in our cohort is attributable
to CG per se rather than the result of other potentially biasing
factors, such as dietary iron deficiency or menstrual blood loss.
The mechanism(s) leading to iron deficiency in (childhood-
onset) CG remain unclear. Although understanding this mecha-
nismwas not the focus of our study, our data indicate neither overt
nor occult gastrointestinal bleeding as underlying causes in most
patients. Nonetheless, it has been previously suggested that iron
deficiency associated with CG is because of chronic bleeding from
dilated capillaries entrapped in the collagen layer of the gastric
mucosa (27). Although clinical and/or endoscopic evidence of
gastric bleeding has been noted in some cases (17,22–24,28,34),
most children with CG seem to lack such signs. Instead of occult
bleeding from the gastric mucosa, one can speculate that the iron
deficiency in these patients results from decreased iron absorption
due to gastric hypochlorhydria or other mechanisms.
Although a few cases of CG and associated common variable
immune deficiency (4,24) or selective IgA deficiency (5) have
previously been reported, such cases were not detected in our
cohort. Moreover, we found no evidence of underlying IgG4-
related disease in any of our patients because none of them had
increased serum levels of IgG4. An indication of an IgG4-related
disease mechanism was previously found in 1 patient with CG
who had IgG4-positive plasma cells in the gastric mucosa (23).
One of the main strengths of the present study is the com-
prehensive clinical, endoscopic, and histologic characterization of
the patients with childhood-onset CG. Furthermore, all eligible
patients in a population-based setting were included. In addition,
detailed follow-up data were available for all patients regarding
the clinical course and endoscopies, with the longest median
follow-up time reported for a cohort of patients with CG. A po-
tential limitation is the relatively small sample size, which is
mitigated by the rarity of the disease.
The main clinical significance of the present study is that it
highlights the chronic nature ofCG in children, therebymotivating
long-term monitoring and follow-up of these patients. Awareness
must be heightened regarding the potentially increased long-term
risk for autoimmune/immune-related diseases. Furthermore, CG
should be suspected in all children with unexplained iron de-
ficiency anemia, and an upper endoscopy needs to be considered,
even in an otherwise asymptomatic patient.
In conclusion, this study shows that childhood-onset CG is
rare, follows a chronic disease course, and has a skewed gender
distribution with female predominance. Although signs of au-
toimmune predisposition were frequent, early development of
autoimmune comorbidities seems to be a rare phenomenon in
childhood-onset CG. Serum calprotectin and amyloid A may
represent novel markers of inflammatory activity in CG.
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Potential competing interests: None to report.
ACKNOWLEDGEMENT
We thank Eva Karlsson, RN, and Birgitta Svensson, RN, for co-
ordination of the clinical visits and expert logistical assistance.
REFERENCES
1. Nielsen OH, Riis LB, Danese S, et al. Proximal collagenous
gastroenteritides: Clinical management. A systematic review. Ann Med
2014;46:311–7.
2. Soeda A, Mamiya T, Hiroshima Y, et al. Collagenous gastroduodenitis
coexisting repeated Dieulafoy ulcer: A case report and review of
collagenous gastritis and gastroduodenitis without colonic involvement.
Clin J Gastroenterol 2014;7:402–9.
3. Al-Kandari A, Al-Alardati H, Sayadi H, et al. An unusual case of
collagenous gastritis in a middle-aged woman with systemic lupus
erythromatosis: A case report. J Med Case Rep 2014;8:278.
4. Mandaliya R, Burkart AL, DiMarino AJ, et al. Association between
common variable immunodeficiency and collagenous infiltrative
disorders of the gastrointestinal tract: A series of four patients. Indian J
Gastroenterol 2016;35:133–8.
5. Anwar MS, Aamar A, Marhaba A, et al. Collagenous gastritis in a young
female with IgA deficiency. Gastroenterol Res 2017;10:126–7.
6. Zamani F, Boghratian A, Zare Mehrjardi A, et al. Collagenous gastritis, a
rare cause of dyspepsia resistant to treatment: A case report.Middle East J
Dig Dis 2018;10:263–6.
7. Akkari I, Skandrani K, Abdelkader AB, et al. Anemia revealing a
collagenous gastritis in a young Tunisian man. Pan Afr Med J 2018;30:
231.
8. Kawasaki K, Fujita Y, Uesugi N, et al. Collagenous gastritis observed by
magnifying narrow-band imaging endoscopy. J Gastrointestin Liver Dis
2018;27:7.
9. Lim HW, Wong BY, Elkowitz D, et al. An elderly patient’s complete
response to steroid therapy for collagenous gastritis. Ther Adv Chronic
Dis 2018;9:143–6.
10. Limaiem F, Mzabi S. Collagenous gastritis: A rare entity. J Interdiscip
Histopathol 2015;3:68–70.
11. Anderson B, Ravi K. Chronic abdominal pain caused by collagenous
gastritis. Clin Gastroenterol Hepatol 2019;17:e144.
12. Hayashi S, Nishida T, Adachi S, et al. Collagenous gastritis: A rare disease
with distinctive endoscopic findings. Gastrointest Endosc 2018;88:186–7.
13. Singh S, Loo LEJ, Watters C, et al. Collagenous panenteritis: A rare cause
of chronic diarrhoea. Frontline Gastroenterol 2017;8:232–5.
14. Sandhu DS, Bellizzi AM, El Abiad R. An elderly woman with upper
abdominal pain and a 60-pound weight loss. Gastroenterology 2018;154:
e14–e15.
15. Bajwa RU, Joshi A, Heikenen JB. Successful treatment of collagenous
gastritis in a child with a gluten-free diet. WMJ 2015;114:271–3.
16. Rosell-Camps A, Riera-Llodra JM, Colom-Segui M, et al. Collagenous
gastritis in the pediatric age. Rev Esp Enferm Dig 2015;107:313–5.
17. Koide T, Mochizuki T, Kawai N, et al. Collagenous gastroduodenitis with
recurrent gastric ulcer in 12-year-old girl. Pediatr Int 2015;57:754–7.
18. Appelman MH, de Meij TG, Neefjes-Borst EA, et al. Spontaneous gastric
perforation in a case of collagenous gastritis. APSP J Case Rep 2016;7:7.
19. Vinsard DG, Mejia Perez LK, Nassar A, et al. Collagenous gastritis and
Helicobacter pylori infection: Amere coincidence? ACGCase Rep J 2017;
4:e69.
20. Eke CB, Brown RA, De Lacy RJ, et al. Collagenous gastritis: An unusual
cause of generalized oedema in a child. J Trop Pediatr 2019;65:305–8.
21. Lee YJ, Lee M, KimDJ, et al. Three case reports of collagenous gastritis in
children: Lessons for an endoscopic and histologic approach to mucosal
nodularity of the stomach. Medicine 2019;98:e14870.
22. Matta J, Alex G, Cameron DJS, et al. Pediatric collagenous gastritis and
colitis: A case series and review of the literature. J Pediatr Gastroenterol
Nutr 2018;67:328–34.
23. Arnason T, Brown IS, Goldsmith JD, et al. Collagenous gastritis: A
morphologic and immunohistochemical study of 40 patients.ModPathol
2015;28:533–44.
24. Ma C, Park JY, Montgomery EA, et al. A comparative clinicopathologic
study of collagenous gastritis in children and adults: The same disorder
with associated immune-mediated diseases. Am J Surg Pathol 2015;39:
802–12.
25. Colletti RB, Cameron DJ, Hassall EG, et al. Collagenous gastritis: An
international puzzle. J Pediatr Gastroenterol Nutr 1998;26:540.
26. Camarero C, Leon F, Colino E, et al. Collagenous colitis in children:
Clinicopathologic, microbiologic, and immunologic features. J Pediatr
Gastroenterol Nutr 2003;37:508–13.
27. Cote JF, Hankard GF, Faure C, et al. Collagenous gastritis revealed by
severe anemia in a child. Hum Pathol 1998;29:883–6.
28. Park S, KimDH,ChoeYH, et al. Collagenous gastritis in aKorean child: A
case report. J Korean Med Sci 2005;20:146–9.
29. RavikumaraM, Ramani P, Spray CH. Collagenous gastritis: A case report
and review. Eur J Pediatr 2007;166:769–73.
30. Leiby A, Khan S, Corao D. Clinical challenges and images in GI.
Collagenous gastroduodenocolitis. Gastroenterology 2008;135:17–9.
31. Wilson C, Thompson K, Hunter C. Nodular collagenous gastritis.
J Pediatr Gastroenterol Nutr 2009;49:157.
32. Brain O, Rajaguru C, Warren B, et al. Collagenous gastritis: Reports and
systematic review. Eur J Gastroenterol Hepatol 2009;21:1419–24.
33. Vella C, Pullicino E, Fearne C, et al. Collagenous gastritis: A rare cause of
anaemia in childhood. Malta Med J 2011;22:34.
34. Colletti RB, Trainer TD. Collagenous gastritis. Gastroenterology 1989;97:
1552–5.
Study Highlights
WHAT IS KNOWN
3 CG is a rare gastrointestinal disorder characterized
histologically by inflammation of the gastric mucosa together
with increased subepithelial deposition of collagen.
3 The clinical picture seems to differ between childhood-onset
and adult-onset disease.
WHAT IS NEW HERE
3 The incidence rate of childhood-onset CG in western Sweden
was 0.25/100,000 person-years of follow-up and significantly
higher for girls than for boys, whereas the disease prevalence
was 2.1/100,000 in children younger than 18 years old.
3 Childhood-onset CG seems to have a chronic disease course
without endoscopic or histologic improvement and is
associated with a high frequency of recurrent iron deficiency.
3 Although heredity for autoimmune disorders and
autoantibodies were commonly detected in the CG cohort,
early development of autoimmune comorbidities was rarely
observed.
3 No clear evidence of an association between childhood-onset
CG and HLA DQ2/DQ8 haplotypes was found.
3 Increased serum levels of calprotectin and amyloid A were
commonly observed and could be useful as markers for
monitoring disease activity.
Clinical and Translational Gastroenterology VOLUME 11 | AUGUST 2020 www.clintranslgastro.com
P
ED
IA
TR
IC
S
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